Sorafenib could suppress tumor growth via NF-κB signaling pathway, but activated NF-κB mediating CD47 up-regulation promoted sorafenib resistance and its blockade synergized the effect of sorafenib in HCC (30). This evidence concerns the gene NFKB1 and hepatocellular carcinoma.